Recent trials in immunosuppression and their consequences for current therapy

Current Opinion in Organ Transplantation

Volumn 19, Issue 4, 2014, Pages 387-394

  Wohlfahrtova, Mariana ^a   Viklicky, Ondrej ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Biomarker driven immunosuppression; Calcineurin inhibitor; Cell therapy; Costimulation blockade; Kidney transplantation

Indexed keywords

ALEMTUZUMAB; BELATACEPT; BIOLOGICAL MARKER; BORTEZOMIB; CALCINEURIN INHIBITOR; COMPLEMENT INHIBITOR; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; RITUXIMAB; STEROID; TACROLIMUS; CALCINEURIN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; ACUTE KIDNEY TUBULE NECROSIS; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG FORMULATION; EFFECTOR CELL; GLOMERULONEPHRITIS; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MEMORY T LYMPHOCYTE; PROTEINURIA; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; RENAL PROTECTION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; GRAFT REJECTION; IMMUNOLOGY; METABOLISM;

ANIMALS; CALCINEURIN; CALCINEURIN INHIBITORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84904179858     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000093     Document Type: Review

References (71)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-2575.
2. Eckardt KU, Kasiske BL. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9:S1-S155.
3. Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for onceversus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9:2505-2513.
4. Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation 2013; 96:897-903.
5. GaberAO, Alloway RR, Bodziak K, et al. Conversion fromtwice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation 2013; 96:191-197.
6. Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant 2013; 13:760-769.
7. de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y. Reduced CO concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90:523-529.
8. Alloway RR, Sadaka B, Trofe-Clark J, et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 2012; 12:2825-2831.
9. Momper JD, Ridenour TA, Schonder KS, et al. The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 2011; 11:1861-1867.
10. Khatami SM, Taheri S, Azmandian J, et al. One-year multicenter double-blind randomized clinical trial on the efficacy and safety of generic cyclosporine (Iminoral) in de novo kidney transplant recipients. Exp Clin Transplant 2013; doi: 10.6002/ect.2013.0139. [Epub ahead of print]
11. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
12. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
13. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-217.
14. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12:630-639.
15. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13:2875-2883.
16. Charpentier B, Medina Pestana JO, Del CRM, et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013; 13:2884-2891.
17. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitorbased regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6:430-439.
18. Goldwater R, Keirns J, Blahunka P, et al. A phase 1, randomized ascending single-dose study of antagonist antihuman CD40 ASKP1240 in healthy subjects. Am J Transplant 2013; 13:1040-1046.
19. Vincenti F, Yang H, Klintmalm G, et al. Clinical outcomes in a phase 1b, randomized, double-blind, parallel group, placebo-controlled, single-dose study of ASKP1240 in de novo kidney transplantation. Am J Transplant 2013; 13 (Suppl 5):86; abstr 181.
20. Ruiz JC, Campistol JM, Grinyo JM, et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78:1312-1318.
21. Guba M, Witzke O, Lehner F, et al. The Herakles study at 24 months: superior renal function in an everolimus-based CNI-free regimen. Transpl Int 2013; 26 (Suppl 2):1-184. (abstr O219).
22. Lehner F, Sommerer C, Witzke O, et al. Herakles at month 24: efficacy and safety of 3 different regimens in de novo renal transplant patients. Transpl Int 2013; 26 (Suppl 2):1-184. (abstr BO148).
23. Rhat T, Sommerer C, Haller H, et al. Outcome on renal function of everolimus conversion in maintenance KTX patients: 4 years Apollo trial. Transpl Int 2013; 26 (Suppl 2):185-339. (abstr P271).
24. Carmellini M, Todeschini P, Manzia TM, et al. Twelve-month outcomes from evidence trial (everolimus once-a-day regimen with cyclosporine versus corticosteroid elimination) in adult kidney transplant recipients. Transpl Int 2013; 26 (Suppl 2):1-184. (abstr O193).
25. Chhabra D, Alvarado A, Dalal P, et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Am J Transplant 2013; 13:2902-2911.
26. Budde K, Lehner F, Sommerer C, et al. Conversion from cyclosporine to everolimus at 4.5 months post-transplant: 3-year results from the randomized ZEUS study. Am J Transplant 2012; 12:1528-1540.
27. Lehner F, Sommerer C, Reinke P, et al. 5-year follow-up on the Zeus KTX trial: everolimus conversion after CNI withdrawal. Transpl Int 2013; 26 (Suppl 2): 1-184. (abstr BO142).
28. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377:837-847.
29. Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12:1192-1198.
30. Silva HT Jr, Felipe CR, Garcia VD, et al. Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 2013; 13:3155-3163.
31. Pascual J, Chadban S, Citterio S, et al. Transform trial design: effect of everolimus on long-term outcomes after kidney transplantation. Transpl Int 2013; 26 (Suppl 2):185-339. (abstr P308).
32. U.S. Renal Data System, USRDS 2013 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
33. Suszynski TM, Gillingham KJ, Rizzari MD, et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. Am J Transplant 2013; 13:961-970
34. Shihab FS, Lee ST, Smith LD, et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. Am J Transplant 2013; 13:474-484.
35. Ciancio G, Gaynor JJ, Guerra G, et al. Randomized trial of three induction antibodies in kidney transplantation: long-term results. Transplantation 2014. [Epub ahead of print]
36. Zhang X, Huang HJ, Han S, et al. Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review. Transplant Immunol 2012; 27:63-68.
37. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364:1909-1919.
38. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9:201-209.
39. Ejaz NS, Shields AR, Alloway RR, et al. Randomized controlled pilot study of B cell- targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant 2013; 13:3142-3154.
40. Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int 2013; 26:563-575.
41. Tyden G, Genberg H, Tollemar J, et al. A randomized, double-blind, placebocontrolled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87:1325-1329.
42. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360:2683-2685.
43. Van Den Hoogen MW, Hilbrands LB. More on B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 361:1215; author reply 1215-1216.
44. Barnett ANR, Asgari E, Chowdhury P, et al. The use of eculizumab in renal transplantation. Clin Transplant 2013; 27:E216-E229.
45. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318-326.
46. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 2011; 11:2523-2527.
47. Canaud G, Kamar N, Anglicheau D, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013; 13:2179-2185.
48. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11:2405-2413.
49. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362:1744-1745.
50. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465.
51. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231-235.
52. Sawitzki B, Schlickeiser S, Reinke P, Volk HD. Monitoring tolerance and rejection in organ transplant recipients. Biomarkers 2011; 16 (Suppl 1):S42-S50.
53. Van Den Boogaardt DE, van Miert PP, de Vaal YJ, et al. The ratio of interferongamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 2006; 82:844-848.
54. Bestard O, Cruzado JM, Lucia M, et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int 2013; 84:1226-1236.
55. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19:1419-1429.
56. Geissler EK, Hutchinson JA. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant 2013; 18:408-415.
57. Casiraghi F, Remuzzi G, Perico N. Mesenchymal stromal cells to promote kidney transplantation tolerance. Curr Opin Organ Transplant 2014; 19:47-53.
58. Geissler EK. The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocytederived cells. Transplant Res 2012; 1:11-13.
59. Zeng H, Yang K, Cloer C, et al. mTORC1 couples immune signals and metabolic programming to establish Treg cell function. Nature 2013; 499:485-490.
60. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant 2014; 14:750-763.
61. Vergani A, Tezza S, Fotino C, et al. The purinergic system in allotransplantation. Am J Transplant 2014; 14:507-514.
62. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted highaffinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11:1149-1159.
63. Cippa PE, Kamarashev J, Chen J, et al. Synergistic Bcl-2 inhibition by ABT- 737 and cyclosporine A. Apoptosis 2013; 18:315-323.
64. Cippa PE, Gabriel SS, Chen J, et al. Targeting apoptosis to induce stable mixed hematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice. Blood 2013; 122:1669-1677.
65. Cippa PE, Gabriel SS, Kraus AK, et al. Bcl-2 inhibition to overcome memory cell barriers in transplantation. Am J Transplant 2014; 14:333-342.
66. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014; 14:59-69.
67. Goto R, You S, Zaitsu M, et al. Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of Foxp3+CD4+ graft infiltrating cells. Am J Transplant 2013; 13:1655-1664.
68. Valenzuela NM, Hong L, Shen XD, et al. Blockade of P-selectin is sufficient to reduceMHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant 2013; 13:299-311.
69. Rostaing L, Charpentier B, Glyda M, et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am J Transplant 2013; 13:1724-1733.
70. Russ GR, Tedesco-Silva H, Kuypers DR, et al. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. Am J Transplant 2013; 13:1746-1756.
71. Wojciechowski D, Vincenti F. Tofacitinib in kidney transplantation. Expert Opin Investig Drugs 2013; 22:1193-1199.